argenx (NASDAQ:ARGX) Stock Price Expected to Rise, JMP Securities Analyst Says

argenx (NASDAQ:ARGX) had its price objective upped by stock analysts at JMP Securities from $497.00 to $606.00 in a report released on Friday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ target price points to a potential upside of 3.36% from the stock’s previous close.

Other analysts also recently issued reports about the stock. Wedbush boosted their target price on shares of argenx from $519.00 to $560.00 and gave the stock an “outperform” rating in a report on Friday, July 26th. Raymond James reaffirmed a “strong-buy” rating and issued a $605.00 price target on shares of argenx in a report on Thursday, October 10th. Guggenheim reaffirmed a “buy” rating and set a $585.00 target price on shares of argenx in a research report on Thursday, September 26th. Wells Fargo & Company increased their price target on argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a research report on Friday, July 26th. Finally, Oppenheimer upgraded argenx from a “market perform” rating to an “outperform” rating and set a $546.00 price objective on the stock in a report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $576.94.

argenx Stock Performance

Shares of NASDAQ ARGX opened at $586.30 on Friday. argenx has a 1 year low of $327.73 and a 1 year high of $589.60. The firm has a market cap of $35.06 billion, a P/E ratio of -166.56 and a beta of 0.63. The stock has a fifty day moving average price of $536.55 and a two-hundred day moving average price of $463.44.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same quarter last year, the company earned ($1.25) EPS. On average, research analysts predict that argenx will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On argenx

Several large investors have recently made changes to their positions in the company. Blue Trust Inc. raised its position in argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock valued at $28,000 after acquiring an additional 62 shares in the last quarter. J.Safra Asset Management Corp increased its stake in shares of argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after purchasing an additional 59 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares in the last quarter. Point72 Hong Kong Ltd acquired a new stake in shares of argenx in the 2nd quarter valued at $76,000. Finally, Cromwell Holdings LLC increased its position in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after buying an additional 66 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.